ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
-
Add time:08/30/2019 Source:sciencedirect.com
SummaryBackgroundGlioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to assess the efficacy and safety of regorafenib in the treatment of recurrent glioblastoma.
We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers
Prev:Lomustine (cas 13010-47-4)
Next:Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ArticlesSingle-agent bevacizumab or Lomustine (cas 13010-47-4) versus a combination of bevacizumab plus Lomustine (cas 13010-47-4) in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial09/04/2019
- Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)09/03/2019
- ArticlesLomustine (cas 13010-47-4)-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial09/02/2019
- Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study09/01/2019
- Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA08/31/2019
- Lomustine (cas 13010-47-4)08/29/2019
- Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA08/28/2019
